Test Price
2,800 AEDโ Home Collection Available
TYK2 Gene (Autosomal Recessive Immunodeficiency Type 35) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
โ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
โ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
โ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation with our genetic counsellors.
โ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The TYK2 gene NGS test analyses the entire coding region to diagnose autosomal recessive immunodeficiency type 35, differentiating it from other primary immunodeficiencies and guiding targeted therapy. This test provides comprehensive analysis of all coding exons and flanking intronic regions of the TYK2 gene using next-generation sequencing technology.
| Feature | Our TYK2 NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 100% coverage of TYK2 exons ยฑ20 bp flanking; sensitivity >99.9% | Broad but may miss deep intronic variants; risk of variants of uncertain significance |
| Method | Targeted NGS (Illumina) with Sanger confirmation | Exome capture NGS, Sanger fill-in |
| Turnaround | 3โ4 Weeks | 8โ12 Weeks |
| Price (AED) | 2,800 | 4,500โ6,000 |
Physician Insight & Safety Protocols
โAs a Consultant Medical Genetics specialising in inherited immune disorders, I recognise that TYK2 deficiency often presents with severe viral infections, atypical mycobacterial disease, or early-onset atopic dermatitis. This targeted NGS test enables precise molecular confirmation essential for initiating appropriate targeted therapy and guiding family cascade screening. However, a negative result does not exclude other primary immunodeficiencies, and comprehensive immunological correlation remains mandatory.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
โ ๏ธ Important Clinical Advisory
Do not alter or discontinue any prescribed immunosuppressive, antimicrobial, or immunomodulatory therapy without prior consultation with your treating physician. Genetic test results must always be interpreted within the full context of clinical presentation, immunological phenotyping, and family history.
Patient Safety & Exclusion Criteria
- Exclusion: This test is not indicated for individuals without clinical suspicion or family history of TYK2-related immunodeficiency. Informed consent and pre-test genetic counselling are mandatory prior to sample collection.
- Emergency Red Flags: If the patient is experiencing life-threatening sepsis, respiratory distress, or severe uncontrolled infection, defer non-urgent genetic testing and seek immediate emergency medical care.
- Paediatric Testing: For minors, legal guardian consent is required in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. The best interest of the child must be determined by a paediatric immunologist.
- Data Privacy: All patient data and genetic information are protected under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Results are released only to the authorised requesting physician.
Patient FAQ & Clinical Guidance
1. What is the TYK2 gene test and why is it performed?
The TYK2 gene NGS test analyses the full coding sequence of the TYK2 gene to diagnose autosomal recessive immunodeficiency type 35. It is performed when a patient presents with clinical features suggestive of primary immunodeficiency, such as recurrent viral infections, atypical mycobacterial infections, or severe eczema, to confirm the diagnosis and guide targeted therapy and family risk assessment.
2. How is the sample collected and what is the turnaround time?
A standard peripheral whole blood sample is collected by our licensed phlebotomists through VIP Mobile Phlebotomy at your home or preferred location, using temperature-controlled cold-chain transport. Results are available within 3โ4 weeks from sample receipt at the laboratory.
3. Is this test covered by health insurance in the UAE?
We provide direct insurance billing verification via WhatsApp at +971 54 548 8731. Many UAE health insurance policies cover medically indicated genetic testing for primary immunodeficiency disorders. Please contact us with your policy details for a pre-authorisation check.
4. What are the benefits of targeted TYK2 gene testing compared to whole exome sequencing?
Targeted TYK2 NGS testing offers higher coverage depth (100% of exons and flanking regions), faster turnaround time (3โ4 weeks vs 8โ12 weeks), lower cost (2,800 AED vs 4,500โ6,000 AED), and reduced risk of incidental findings or variants of uncertain significance compared to whole exome sequencing for this specific indication.
UAE Regulatory & Data Privacy Adherence
Data Protection Framework: Your genetic and personal data are processed in full compliance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All results are securely transmitted and accessible only to the requesting physician.
Medical Liability: Patient safety, informed consent, and clinical governance follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring the highest standards of care.
Accreditation: DNA Labs UAE operates under DHA Facility License Number 1143 and is ISO 9001:2015 accredited (Cert: INT/EGQ/2509DA/3139), guaranteeing rigorous quality management across all diagnostic processes.
Clinical & Logistical Metadata
| Test Name | TYK2 Gene (Autosomal Recessive Immunodeficiency Type 35) NGS Sequencing Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (3โ5 mL in EDTA tube); also accepted: extracted DNA (2 ยตg) or FTA card dried blood spot |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) on Illumina platform with confirmatory Sanger sequencing of all detected variants |
| ICD-10-CM Code | D81.8 (Other combined immunodeficiencies) |
| LOINC Code | 81247-9 (Gene targeted mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians